Broadwood Partners, L.P. Buys 93,124 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 93,124 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were acquired at an average cost of $17.54 per share, for a total transaction of $1,633,394.96. Following the completion of the acquisition, the insider now owns 12,074,275 shares of the company’s stock, valued at $211,782,783.50. This trade represents a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The stock was bought at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The stock was purchased at an average price of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The stock was purchased at an average cost of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The shares were purchased at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Down 1.1 %

Shares of NASDAQ STAA opened at $17.72 on Friday. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $52.68. The firm has a market cap of $874.04 million, a P/E ratio of -43.22 and a beta of 0.66. The business’s 50 day moving average price is $19.87 and its 200 day moving average price is $25.70.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. StockNews.com cut STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. Mizuho lowered STAAR Surgical from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Stephens reiterated an “equal weight” rating and issued a $17.00 target price on shares of STAAR Surgical in a research note on Tuesday. Finally, Piper Sandler cut their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $25.29.

Institutional Trading of STAAR Surgical

Several large investors have recently made changes to their positions in the business. Broadwood Capital Inc. lifted its position in STAAR Surgical by 0.7% during the fourth quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier’s stock valued at $263,513,000 after purchasing an additional 80,200 shares during the period. Vanguard Group Inc. lifted its holdings in shares of STAAR Surgical by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after buying an additional 319,441 shares during the period. State Street Corp boosted its stake in shares of STAAR Surgical by 0.5% in the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock worth $72,092,000 after buying an additional 10,430 shares during the last quarter. Resona Asset Management Co. Ltd. purchased a new stake in shares of STAAR Surgical in the fourth quarter worth about $36,411,000. Finally, Geode Capital Management LLC grew its holdings in STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after acquiring an additional 31,212 shares during the period. 96.70% of the stock is owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.